Claude-enabled protein binder design has produced a meaningful experimental signal in a TREM2 campaign, but the result should be read as evidence of progress in AI-assisted biotech tooling rather than proof of faster drug discovery. In a February 2026 one-day hackathon organized by muni, autonomous AI agents including Claude Sonnet 4.6 submitted designs that were subsequently tested in the wet lab by Adaptyv Bio. The screen evaluated 35 agent-designed binders, of which 12 bound TREM2, for...